Blood tests could track rare immune disease APDS
NCT ID NCT06694363
First seen Mar 25, 2026 · Last updated Jun 20, 2026 · Updated 10 times
Summary
This study aims to find new biomarkers in blood, urine, and stool to better screen and monitor Activated PI3K Delta Syndrome (APDS), a rare immune disorder. Researchers will collect samples from 14 patients over two years, including those starting a PI3K inhibitor treatment. The goal is to identify markers that reflect disease severity and treatment response, using advanced lab techniques.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACTIVATED PI3K DELTA SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU IUCT Oncopole - TOULOUSE
NOT_YET_RECRUITINGToulouse, France
Contact Email: •••••@•••••
-
Hôpital Haut Levêque - BORDEAUX
NOT_YET_RECRUITINGBordeaux, 33000, France
Contact Email: •••••@•••••
-
Hôpital Jeanne de Flandres - LILLE
RECRUITINGLille, 59000, France
Contact Email: •••••@•••••
-
Hôpital La Timone adulte - MARSEILLE
NOT_YET_RECRUITINGMarseille, 13000, France
Contact Email: •••••@•••••
-
Hôpital Necker Enfants Malades - PARIS
RECRUITINGParis, 75015, France
Contact Email: •••••@•••••
-
Hôpital Pellerin Enfants - BORDEAUX
NOT_YET_RECRUITINGBordeaux, 33000, France
Contact Email: •••••@•••••
-
Hôpital des enfants - TOULOUSE
NOT_YET_RECRUITINGToulouse, France
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to better ways to monitor APDS disease activity and response to treatment using simple blood tests.
What could go wrong
This is a very small, early-stage study (14 participants) focused on finding biomarkers, not testing a treatment. The results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.